Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Top Page
Alterity Therapeutics
(Sydney:ATH)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:11/01/25
Alterity Therapeutics faces significant challenges with profitability and cash flow, despite strong revenue growth and a solid equity position. The technical indicators suggest bearish momentum, and the negative P/E ratio highlights ongoing financial struggles. These factors contribute to a low overall stock score.
Positive Factors
Targeted neurodegenerative pipeline
A concentrated R&D focus on disease‑modifying small molecules for neurodegenerative disorders (lead program ATH434 for MSA) is a durable strategic advantage: it aligns with growing unmet medical need, concentrates scientific expertise, and increases attractiveness for long‑term partnership or licensing outcomes if clinical progress continues.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow, with FCF declining ~30%, signals ongoing cash burn that will require external financing. For a pre‑commercial biotech this creates structural funding risk, potential dilution through frequent equity raises, and constrains the company’s ability to advance multiple programs in parallel.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted neurodegenerative pipeline
A concentrated R&D focus on disease‑modifying small molecules for neurodegenerative disorders (lead program ATH434 for MSA) is a durable strategic advantage: it aligns with growing unmet medical need, concentrates scientific expertise, and increases attractiveness for long‑term partnership or licensing outcomes if clinical progress continues.
Read all positive factors
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$97.88M
Dividend YieldN/A
Average Volume (3M)16.33M
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth63.46%
CountryAU
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.56M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its prop...
How the Company Makes Money
Alterity Therapeutics generates revenue primarily through a combination of research and development funding, collaborations, and potential licensing agreements. The company may receive milestone payments and royalties from partnerships with larger...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 3.71M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -20.11M | -14.63M | -19.46M | -17.51M | -17.39M | -19.36M |
| Net Income | -14.59M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 56.92M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 49.20M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 163.91K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 2.65M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 54.27M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.36M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -12.98M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | 0.00 | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 44.44M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.58B | 78.41 | 9.20% | ― | 12.35% | 26.73% | |
56 Neutral | AU$70.05M | -7.57 | -179.37% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$48.52M | -9.56 | -104.56% | ― | ― | ― | |
43 Neutral | AU$136.48M | -4.28 | -134.14% | ― | ― | 10.91% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | ― | |
41 Neutral | AU$97.88M | -2.12 | -30.19% | ― | ― | 63.46% |
* Healthcare Sector Average
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ACW
Actinogen Medical
0.04
<0.01
31.03%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
59.46%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-9.09%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:NEU
Neuren Pharmaceuticals Limited
12.52
1.39
12.49%
Alterity Therapeutics Corporate Events
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
Apr 1, 2026
Alterity Therapeutics has released a corporate presentation dated April 2026 that includes cautionary language regarding forward‑looking statements. The company emphasizes that projections and statements about its plans, objectives, expectat...
Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan
Mar 29, 2026
Alterity Therapeutics has received positive written feedback from the U.S. Food and Drug Administration following a Type C Meeting on its planned Phase 3 development program for ATH434 in Multiple System Atrophy. The regulator supported the compan...
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
Mar 26, 2026
Alterity Therapeutics has notified the market of the planned issue of 61,500,000 unlisted options under its employee incentive scheme. The options, which carry an exercise price of US$0.0057 and expire on March 26, 2031, are not intended to be quo...
Alterity Therapeutics Plans Issue of 150 Million Options on ASX
Mar 19, 2026
Alterity Therapeutics has notified the ASX of a proposed issue of up to 150 million options as part of a placement or similar capital-raising structure. The new options will carry an exercise price of A$0.02 and will expire five years after their ...
Alterity Therapeutics Launches Facility to Sell Small Share Parcels
Mar 12, 2026
Alterity Therapeutics has introduced an opt-out unmarketable parcel sale facility for shareholders holding less than A$500 worth of its fully paid ordinary shares, aiming to give these investors a cost-free way to exit positions that might otherwi...
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
Mar 9, 2026
Alterity Therapeutics, a clinical-stage biotech focused on disease-modifying treatments for Multiple System Atrophy and related Parkinsonian disorders, is advancing its lead asset ATH434 following positive Phase 2 data and leveraging a discovery p...
Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial
Mar 3, 2026
Alterity Therapeutics has appointed neurologist and movement disorder expert Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, while he maintains his professorship at Vanderbilt University Medical Center. Claassen, an internationally recog...
Alterity Widens Half-Year Loss but Lifts Asset Backing on Higher Interest Income
Feb 26, 2026
Alterity Therapeutics reported a sharp increase in half-year revenue to A$909,750 for the six months to 31 December 2025, driven entirely by higher interest income on its bank balances, while remaining a pre-revenue biotech with no dividend paymen...
Alterity Sharpens ATH434 Phase 3 Plans as Phase 2 MSA Data Strengthen
Jan 30, 2026
Alterity Therapeutics reported a robust second quarter of FY26, highlighting strengthened Phase 2 data for its lead MSA candidate ATH434, further detailed through additional analyses and multiple international scientific presentations that reinfor...
Alterity Therapeutics Advances Lead MSA Drug Toward Phase 3 After Strong Phase 2 Data
Jan 21, 2026
Alterity Therapeutics reported that it successfully completed its Phase 2 clinical program for lead candidate ATH434 in multiple system atrophy during 2025, with data showing the drug was safe, well-tolerated, and associated with slowing disease p...
Alterity Therapeutics Issues 43.5 Million Unlisted Options Under Employee Incentive Scheme
Jan 15, 2026
Alterity Therapeutics Limited has notified the market of the issue of 43.5 million unlisted options under an employee incentive scheme, with an exercise price of US$0.0057 and an expiry date of 13 January 2031. The options, which will not be quote...
Alterity Therapeutics Issues 18 Million Unlisted Options Under Employee Scheme
Jan 15, 2026
Alterity Therapeutics has notified the market of the issue of 18 million unlisted options under its employee incentive scheme, each exercisable at $0.008 and expiring on 9 January 2031. The move expands the company’s pool of unquoted equity-...
Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation
Jan 13, 2026
Alterity Therapeutics has released a brief corporate communication noting that some of its January 2026 corporate presentation may include statements that qualify as forward-looking under U.S. securities laws. The company cautions that such statem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.